

Editor Note on Diabetes

ARCHIL K

The world over, the high obesity rate has become a burden, and the dire need to bring it under control has risen as a result. World Health Organization (WHO) suggests that over 50% of the worldwide population is obese. Furthermore, in the year 2014, over 1.9 billion adults that were 18 years and above were overweight. Out of these, more than 600 million were reported obese. Obesity is connected to various chronic diseases, including hypertension, orthopedic disorders, diabetes, and cancer.

At present, numerous solutions including exercise, diet, minimally invasive devices & implants, invasive surgeries, and drugs, are available to manage weight. Obesity refers to a multifactorial disease that involves several genetic as well as physiological factors contributing to disease progression. As the results of monotherapy are limited; a holistic approach to achieve effective obesity control has become necessary. Owing to this, a combination of drugs finds widespread use in the treatment of obesity. Successful clinical trials and the consequent emergence of advanced and innovative products like satiety drugs are projected to create growth opportunities for the market in the following years.

Gastric bypass procedure is considered the most popular bariatric surgery, followed by minimally invasive procedures. Shorter hospital stays, cost-effectiveness, and speedy recovery are few prominent factors elevating the demand for minimally invasive surgeries. Additionally, government initiatives with the aim of augmenting the adoption rate of minimally invasive surgeries to decrease the incidence of hospital-acquired infections, as well as hospital readmissions, will stimulate market growth as well.

investments for the development of effective weight management solutions along with the commercial availability of minimally invasive procedures in the region favor market growth.

Bagging the second position in the global obesity treatment market, Europe benefits from the availability of funds for research, expanding obese population, and rising adoption of bariatric surgeries.

Developing at the fastest-rate, the Asia Pacific market is backed by the increasing awareness of adverse health effects associated with overweight along with its impact amongst the regional population. Other beneficial factors include the growing disposable income, improving healthcare infrastructure, and the thriving medical tourism industry.

Lastly, Middle East and Africa is counted as the least profitable obesity treatment market. Poor economy and strict government policies, mostly in Africa, have a big hand in the abysmal performance of the overall market in the region.

